This Phase 1 study evaluated efficacy/safety of inhaled single-dose MK-5475, an investigational, small-molecule stimulator of soluble guanylate cyclase designed for inhaled delivery via a dry-powder inhaler device, in participants with pulmonary arterial hypertension.
The findings reveal that treatment with inhaled single-dose MK-5475 reduced pulmonary vascular resistance and increased pulmonary blood volume. Compared to the placebo, MK-5475 was well tolerated without causing vasodilatory systemic side effects. This study, conducted on adult participants with pulmonary arterial hypertension, showcases the promising pulmonary selectivity and favourable safety/tolerability profile of MK-5475, laying the groundwork for further clinical development.
Sponsor Merck Sharp & Dohme LLC
The full article is available at this link on the ELSEVIER web page
Citation
Ednan K. Bajwa, Dawn Cislak, John Palcza, Hwa-ping Feng, Eric J. Messina, Tom Reynders, Jean-François Denef, Vasile Corcea, Eseng Lai, S. Aubrey Stoch,
Effects of an inhaled soluble guanylate cyclase (sGC) stimulator MK-5475 in pulmonary arterial hypertension (PAH), Respiratory Medicine, Volume 206, 2023,107065, ISSN 0954-6111, https://doi.org/10.1016/j.rmed.2022.107065.